米国市場銘柄情報

CERS シーラス

銘柄追加

1.750
+0.040+2.34%

終値 04/29 16:00 ET

1.760
+0.010+0.57%

市場後 17:38 ET

3.24億時価総額-8333直近PER

シーラスに関するコメント

ログインコメントを投稿

hard-working Camel_4

03/26 21:11

$シーラス(CERS.US)$ Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

$シーラス(CERS.US)$ 🚀🚀🚀

$シーラス(CERS.US)$ Cerus Announces Positive Results For Phase 3 Trial Of Intercept Blood System

Trytosaveabit

03/19 20:51

$シーラス(CERS.US)$ That gap at 2.11 almost filled!

Trytosaveabit

03/19 20:32

$シーラス(CERS.US)$ Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs

Moomoo AI

02/07 18:41

Despite recent uplift, the business needs to justify a higher price. Market focus is on revenue growth due to unprofitability. Fast revenue growth doesn't guarantee profits, and if cash is low, capital may need to be raised. Investors should note the 3 warning signs with Cerus.

Cerus (NASDAQ:CERS) Shareholders Are up 23% This Past Week, but Still in the Red Over the Last Three Years

Moomoo AI

01/22 05:54

Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.

Cantor Picks RCEL as Best 2024 Medtech Idea; Bullish on PACB, AXGN, CERS

Moomoo AI

2023/10/07 22:08

Despite notable revenue growth, Cerus' continual drop in share price indicates potential balance sheet issues. This may raise concerns about capital acquisition need. However, contrarian investors may eye the stock hoping for a turnaround.